Abstract 5783
Background
Six anti–PD-1/PD-L1 agents have been FDA approved for various cancers. Despite a lack of head-to-head trials, there is a perception that the irAE profiles are comparable between agents. We hypothesized that the irAE profiles vary between anti–PD-1 and anti–PD-L1 agents and among individual agents. Since prospective comparison is unlikely, we conducted a trial-level meta-analysis of irAEs reported in phase I–IV trials evaluating anti–PD-1/L1 agents in various tumor types.
Methods
We analyzed data from 35 manuscripts reporting phase I (n = 18), 2 (n = 15), 3 (n = 9) or 4 (n = 1) trials, comprising 8,730 patients treated with anti–PD-1/PD-L1 monotherapy. The incidence and odds ratios (ORs) for selected clinically relevant irAEs (colitis, elevated AST, hypothyroidism, pneumonitis or rash; any grade and grade ≥3) and irAEs overall were estimated using random-effects models for anti–PD-L1 agents atezolizumab, avelumab and durvalumab; for anti–PD-1 agents nivolumab and pembrolizumab; and as pooled estimates for anti–PD-1 and anti–PD-L1 agents.
Results
The risk of any grade (OR = 4.34) and grade ≥3 rash (OR = 4.38); grade ≥3 hypothyroidism (OR = 2.85); any grade (OR = 2.53) and grade ≥3 colitis (OR = 3.79); and any grade ≥3 irAE (OR = 1.89) was higher with anti–PD-1 vs anti–PD-L1 agents. When comparing the risk of all selected irAEs for each agent with pooled estimates for all other agents combined, atezolizumab had the lowest risk, followed by avelumab; pembrolizumab had a higher risk, except for grade ≥3 elevated AST. In pairwise comparisons, the risks associated with atezolizumab vs avelumab were not significantly different, likewise for nivolumab vs pembrolizumab. The largest decrease in risk for all grade ≥3 irAEs except elevated AST was for avelumab vs pembrolizumab.
Conclusions
Overall, the risk of grade ≥3 irAEs was higher with anti–PD-1 vs anti–PD-L1 agents. Compared with other agents, avelumab had a lower risk of individual grade ≥3 irAEs except elevated AST, whereas atezolizumab had the lowest risk of irAEs of any grade. Limitations include the retrospective nature of the meta-analysis and varied tumor types, trial designs, treatment durations and irAE evaluations.
Clinical trial identification
Editorial acknowledgement
ClinicalThinking, funded by Merck Healthcare KGaA and Pfizer Inc.
Legal entity responsible for the study
Merck Healthcare KGaA.
Funding
Merck Healthcare KGaA and Pfizer Inc.
Disclosure
G.P. Sonpavde: Honoraria (self): UpToDate; Advisory / Consultancy: Agensys; Advisory / Consultancy: Astellas Pharma; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: Eisai; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Genentech; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution): Merck & Co.; Advisory / Consultancy: Novartis; Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Speaker Bureau / Expert testimony: Clinical Care Options/NCCN; Speaker Bureau / Expert testimony: Onclive; Speaker Bureau / Expert testimony: Physician Education Resource; Speaker Bureau / Expert testimony: Research to Practice; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Onyx; Research grant / Funding (institution): Pfizer. P. Grivas: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Biocept; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Clovis Oncology; Advisory / Consultancy: Driver, Inc; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Foundation Medicine; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy: Heron; Advisory / Consultancy, Research grant / Funding (institution): Merck & Co.; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy: QED Therapeutics; Advisory / Consultancy: Seattle Genetics; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Mirati Therapeutics; Research grant / Funding (institution): Oncogenex. D. Hennessy: Full / Part-time employment: EMD Serono. J.D. Hunt: Full / Part-time employment: EMD Serono. All other authors have declared no conflicts of interest.
Resources from the same session
3839 - Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations.
Presenter: Tomasz Wróbel
Session: Poster Display session 3
Resources:
Abstract
3842 - Effect of docetaxel-resistance on the reactivity of prostate cancer cells to metformin
Presenter: Jessica Catapano
Session: Poster Display session 3
Resources:
Abstract
5198 - Cell plasticity and taxanes resistance in metastatic prostate cancer: ESRP1 as a predictive biomarker of taxane response
Presenter: Natalia Jimenez
Session: Poster Display session 3
Resources:
Abstract
2981 - Effect of Selumetinib plus AZD8186 treatment on Cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines
Presenter: Vicenc Ruiz de Porras
Session: Poster Display session 3
Resources:
Abstract
2779 - Anti-tumor activity of cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, in pancreatic ductal adenocarcinoma cells
Presenter: Majid Momeny
Session: Poster Display session 3
Resources:
Abstract
1782 - The molecular mechanisms of EpCAM in regulating tumor progression and development of anti-EpCAM antibodies for colon cancer diagnosis and therapy
Presenter: Han-chung Wu
Session: Poster Display session 3
Resources:
Abstract
1322 - Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients
Presenter: Jens Hahne
Session: Poster Display session 3
Resources:
Abstract
1579 - Serum exosomal microRNA-199b-5p as a novel circulating biomarker to predict response of preoperative chemoradiotherapy for locally advanced rectal cancer
Presenter: Dong Won Baek
Session: Poster Display session 3
Resources:
Abstract
1761 - Live biobank of patient-derived organoids from Thai colorectal cancer patients enables clinical outcome prediction
Presenter: Pariyada Tanjak
Session: Poster Display session 3
Resources:
Abstract
3542 - The biological implications of PDCD6 dysregulation in colorectal cancer
Presenter: Romina Briffa
Session: Poster Display session 3
Resources:
Abstract